PepGen Inc. ( (PEPG) ) has released its Q2 earnings. Here is a breakdown of the information PepGen Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, headquartered in Boston, Massachusetts. In its latest earnings report for the quarter ended June 30, 2025, PepGen Inc. reported a net loss of $23.1 million, reflecting a decrease from the previous year. The company’s operating expenses were primarily driven by research and development costs, which amounted to $18.4 million for the quarter. Despite the losses, PepGen maintains a cash position of $74.7 million, which is expected to fund operations into the second quarter of 2026. The company is actively seeking additional funding to continue its operations and advance its clinical programs. Looking forward, PepGen’s management remains focused on the development of its remaining clinical-stage product candidate, PGN-EDODM1, while navigating financial challenges and competitive pressures in the biotechnology sector.